Illumina (ILMN - Free Report) reported $1.12 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 3.6%. EPS of $0.14 for the same period compares to $0.14 a year ago.
The reported revenue represents a surprise of +3.11% over the Zacks Consensus Estimate of $1.09 billion. With the consensus EPS estimate being $0.01, the EPS surprise was +1300.00%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Illumina performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- GRAIL: $30 million versus $26.26 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +30.4% change.
- Revenue- Microarrays- Instruments: $6 million compared to the $4.63 million average estimate based on four analysts. The reported number represents a change of +20% year over year.
- Revenue- Service and other revenue: $199 million versus the four-analyst average estimate of $187.72 million. The reported number represents a year-over-year change of +17.1%.
- Revenue- Microarrays- Consumables: $74 million compared to the $76.71 million average estimate based on four analysts. The reported number represents a change of -7.5% year over year.
- Revenue- Product revenue: $923 million compared to the $889.86 million average estimate based on four analysts. The reported number represents a change of +1.1% year over year.
- Revenue- Sequencing- Instruments: $161 million compared to the $142.78 million average estimate based on four analysts. The reported number represents a change of +10.3% year over year.
- Revenue- Sequencing- Consumables: $687 million versus the four-analyst average estimate of $665.74 million. The reported number represents a year-over-year change of 0%.
- Revenue- Microarrays- Total: $97 million versus the three-analyst average estimate of $103.76 million. The reported number represents a year-over-year change of -4%.
- Revenue- Sequencing- Total: $1 billion compared to the $955.79 million average estimate based on three analysts. The reported number represents a change of +3.7% year over year.
- Revenue- Core Illumina: $1.10 billion compared to the $1.05 billion average estimate based on three analysts. The reported number represents a change of +3% year over year.
- Revenue- Sequencing- Service & Other: $152 million compared to the $181.18 million average estimate based on three analysts. The reported number represents a change of +16% year over year.
- Revenue- Microarrays- Service & Other: $17 million versus $19.62 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +6.3% change.
View all Key Company Metrics for Illumina here>>>Shares of Illumina have returned +1.6% over the past month versus the Zacks S&P 500 composite's +6.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Illumina (ILMN - Free Report) reported $1.12 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 3.6%. EPS of $0.14 for the same period compares to $0.14 a year ago.
The reported revenue represents a surprise of +3.11% over the Zacks Consensus Estimate of $1.09 billion. With the consensus EPS estimate being $0.01, the EPS surprise was +1300.00%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Illumina performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- GRAIL: $30 million versus $26.26 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +30.4% change.
- Revenue- Microarrays- Instruments: $6 million compared to the $4.63 million average estimate based on four analysts. The reported number represents a change of +20% year over year.
- Revenue- Service and other revenue: $199 million versus the four-analyst average estimate of $187.72 million. The reported number represents a year-over-year change of +17.1%.
- Revenue- Microarrays- Consumables: $74 million compared to the $76.71 million average estimate based on four analysts. The reported number represents a change of -7.5% year over year.
- Revenue- Product revenue: $923 million compared to the $889.86 million average estimate based on four analysts. The reported number represents a change of +1.1% year over year.
- Revenue- Sequencing- Instruments: $161 million compared to the $142.78 million average estimate based on four analysts. The reported number represents a change of +10.3% year over year.
- Revenue- Sequencing- Consumables: $687 million versus the four-analyst average estimate of $665.74 million. The reported number represents a year-over-year change of 0%.
- Revenue- Microarrays- Total: $97 million versus the three-analyst average estimate of $103.76 million. The reported number represents a year-over-year change of -4%.
- Revenue- Sequencing- Total: $1 billion compared to the $955.79 million average estimate based on three analysts. The reported number represents a change of +3.7% year over year.
- Revenue- Core Illumina: $1.10 billion compared to the $1.05 billion average estimate based on three analysts. The reported number represents a change of +3% year over year.
- Revenue- Sequencing- Service & Other: $152 million compared to the $181.18 million average estimate based on three analysts. The reported number represents a change of +16% year over year.
- Revenue- Microarrays- Service & Other: $17 million versus $19.62 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +6.3% change.
View all Key Company Metrics for Illumina here>>>Shares of Illumina have returned +1.6% over the past month versus the Zacks S&P 500 composite's +6.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Get the latest research report on ILMN - FREE